Qprotyn achieves viscosity of 18cP for 250mg/mL of Trastuzumab using its HILOPRO® technology.
Upgrading Trastuzumab from IV to Subcutaneous (SubQ) administration may now be possible without expensive, high-volume hyaluronidase injections. With HILOPRO technology Without viscosity-reducing excipients Due to patients’ convenience of at-home administration and reduced number of hospital visits as well as the reduction in treatment costs, SubQ administration of biologics is of increasing interest. Trastuzumab targets Human IgG1/TNFα and is approved for breast cancer, gast